NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$419.8m

Last Updated

2021/04/16 23:47 UTC

Data Sources

Company Financials +

Executive Summary

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Harmony Biosciences Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HRMY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: HRMY's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-0.6%

HRMY

2.3%

US Pharmaceuticals

1.3%

US Market


1 Year Return

n/a

HRMY

8.9%

US Pharmaceuticals

53.9%

US Market

Return vs Industry: Insufficient data to determine how HRMY performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HRMY performed against the US Market.


Shareholder returns

HRMYIndustryMarket
7 Day-0.6%2.3%1.3%
30 Day-8.5%1.3%3.3%
90 Day-27.5%-0.6%8.9%
1 Yearn/a13.1%8.9%56.6%53.9%
3 Yearn/a38.5%26.5%64.4%53.6%
5 Yearn/a46.8%27.7%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is Harmony Biosciences Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Harmony Biosciences Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HRMY ($28.28) is trading below our estimate of fair value ($180.88)

Significantly Below Fair Value: HRMY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HRMY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: HRMY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HRMY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HRMY is overvalued based on its PB Ratio (16.6x) compared to the US Pharmaceuticals industry average (3.8x).


Future Growth

How is Harmony Biosciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

43.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HRMY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: HRMY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HRMY's is expected to become profitable in the next 3 years.

Revenue vs Market: HRMY's revenue (28.9% per year) is forecast to grow faster than the US market (9.4% per year).

High Growth Revenue: HRMY's revenue (28.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HRMY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Harmony Biosciences Holdings performed over the past 5 years?

65.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: HRMY is currently unprofitable.

Growing Profit Margin: HRMY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if HRMY's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare HRMY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HRMY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).


Return on Equity

High ROE: HRMY has a negative Return on Equity (-38.02%), as it is currently unprofitable.


Financial Health

How is Harmony Biosciences Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: HRMY's short term assets ($262.9M) exceed its short term liabilities ($134.5M).

Long Term Liabilities: HRMY's short term assets ($262.9M) exceed its long term liabilities ($195.4M).


Debt to Equity History and Analysis

Debt Level: HRMY's debt to equity ratio (199.9%) is considered high.

Reducing Debt: Insufficient data to determine if HRMY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HRMY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if HRMY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Harmony Biosciences Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HRMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HRMY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HRMY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HRMY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HRMY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

John Jacobs (52 yo)

2.83yrs

Tenure

US$845,663

Compensation

Mr. John Charles Jacobs, MBA, serves as President and Chief Executive Officer of Harmony Biosciences, LLC. He served as Chairman of Harmony Biosciences, LLC.., since 2019 until March 2020. He serves as Pre...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD845.66K) is below average for companies of similar size in the US market ($USD1.56M).

Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.


Leadership Team

Experienced Management: HRMY's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: HRMY's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: HRMY only recently listed within the past 12 months.


Top Shareholders

Company Information

Harmony Biosciences Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Harmony Biosciences Holdings, Inc.
  • Ticker: HRMY
  • Exchange: NasdaqGM
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$419.788m
  • Shares outstanding: 56.89m
  • Website: https://www.harmonybiosciences.com

Number of Employees


Location

  • Harmony Biosciences Holdings, Inc.
  • 630 West Germantown Pike
  • Suite 215
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings


Biography

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for th...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/16 23:47
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.